The most prevalent malignancy in US men is prostate cancer. Appropriate treatment regimen is dependent on accurate tumor staging. Pelvic multiparametric MR (mpMRI) is the established modality for tumor and nodal staging. C-11 choline is FDA approved in diagnosis of recurrent prostate cancer. Introduction of a hybrid time-of-flight PET/MR system affords the opportunity to perform a combined C-11 choline PET + mpMRI for prostate cancer staging. We feel this system would be beneficial in staging of treatment naïve high risk prostate cancer.